[AME] AMETEK: Q3 2026 Earnings Test Record Orders and Indicor Costs

AMETEK, an industrial technology company based in Berwyn, Pennsylvania, sells instruments and precision components into niche markets such as process analysis, power, aerospace and defense, automation and medical through its Electronic Instruments Group (EIG) and Electromechanical Group (EMG)[1]. The company is scheduled to report AMETEK Q3 2026 earnings on 2026-11-03, covering the Third quarter 2026 (three months ended September 30, 2026)[2]. In the latest disclosed quarter, the second quarter of 2026, sales were $2,044.4 million, up 15.0%, with 10% organic growth and 5% from acquisitions; orders were $2,284.0 million, up 28.2%, and the backlog of unfilled orders reached a record $4,110.2 million on June 30[3]. Adjusted earnings per share were $2.09 in that quarter, up 17%, against GAAP EPS of $1.77; on August 4 management guided third-quarter sales up high single digits and adjusted EPS of $2.08 to $2.10, and raised full-year adjusted EPS guidance to $8.20 to $8.30[4]. That guidance came before the Indicor deal closed on August 26, and the closing announcement only said Indicor should add about $350 million to 2026 sales[5]. Analyst estimates compiled by Drillr put third-quarter revenue consensus at $2,122.0 million (10 analysts, range $2,102.4 million to $2,151.5 million), third-quarter EPS consensus at $2.11 (12 analysts) and full-year EPS consensus at $8.38, all slightly above the top of company guidance; the data source does not state whether these estimates include Indicor, so their basis may differ from the guidance[6].

Three things matter most in this report. The first is whether the instruments segment can turn orders into revenue: organic orders grew 22% and 25% in the first two quarters, but EIG organic sales grew only 7% in the second quarter, so whether EIG organic growth holds at 7% or better in the third quarter will show whether the record backlog is converting into revenue or simply piling up[7][3]. The second is whether the electromechanical segment can hold its margin against a tougher comparison: EMG's operating margin rose to 26.2% in the second quarter, and management warned in the first quarter that EMG faces tough comparisons later in the year, so a third-quarter margin still above 25% would indicate that the expansion comes from durable volume leverage[3][8]. The third is the first appearance of the $5 billion Indicor acquisition in the results: whether the company discloses Indicor's sales contribution, post-closing interest and integration costs, and whether the gap between GAAP and adjusted EPS widens well beyond the second quarter's $0.32, will decide whether the raised full-year guidance holds up under the new debt[5][4].

Company Background and Business Structure

AMETEK is an industrial technology company that grows through niche-market instruments and a steady stream of acquisitions. It is listed on the New York Stock Exchange under the ticker AME and, by its August 26 description, has annualized sales of about $9.0 billion across a range of niche markets[5]. In 2025 the company spent $933.2 million to buy Kern Microtechnik and FARO Technologies, with FARO bringing about $340 million of annual sales into EIG[9]; in 2026 it bought LKC Technologies in January and First Aviation Services in May, paying $424.5 million in total during the first half[3]. First Aviation provides defense and aviation maintenance, repair and overhaul services, has about $80 million of annual revenue and joined EMG[10], while the Indicor Instrumentation purchase completed on August 26 was a $5.0 billion all-cash transaction[5].

The Electronic Instruments Group is the core of the company's revenue and profit. In 2025 EIG had sales of $4,919.1 million, operating income of $1,447.1 million and an operating margin of 29.4%; process and analytical instrumentation made up 70% of EIG sales, 52% of EIG sales went to customers outside the United States, and the five largest customers accounted for only about 4%[9]. Management cited RTDS Technologies winning a major power-system simulation order from a data center hyperscaler and Zygo's precision metrology and optical solutions being designed into leading advanced AI semiconductor manufacturing platforms[11]. By product line, second-quarter 2026 sales were $944.0 million in process and analytical instrumentation, $599.1 million in aerospace and power, and $501.3 million in automation and engineered solutions[3].

The Electromechanical Group is smaller but has improved its margin fastest over the past two years. In 2025 EMG had sales of $2,482.0 million and operating income of $578.9 million, and its operating margin rose from 20.0% in 2024 to 23.3%; automation and engineered solutions made up 70% of EMG sales, serving semiconductor, laboratory and medical equipment and including single-use surgical instruments, implantable components and drug delivery systems, while aerospace made up 30%; 42% of EMG sales went outside the United States, the five largest customers accounted for about 15%, and no single customer exceeded 5% of company sales[9]. Management attributes most of EMG's recent profit growth to Paragon, its medical components business[11], while the newly acquired Indicor businesses are being split between EIG and EMG by product and market, with a large share of revenue from consumables, services and aftermarket support[1].

Financial History and Current Position

2025 was a year of slow revenue growth in which orders recovered first. Full-year sales were $7,401.1 million, up 6.6% from $6,941.2 million in 2024, with 4% from acquisitions, 2% organic growth and 1% from currency; operating income was $1,910.3 million for a 25.8% margin, interest expense was $81.3 million, net income was $1,480.1 million and diluted EPS was $6.40[9]. Operating cash flow was $1,801.8 million and free cash flow was $1,671.6 million; orders rose 11.3% to $7,579.4 million (4% organic), year-end backlog was $3,581.5 million, and total debt, net was $2,283.3 million, including $740.0 million of commercial paper[9]. The two segments diverged sharply, with EIG organic sales down 1% and EMG organic sales up 8%[9].

In the first half of 2026, the order acceleration began to reach revenue. First-quarter sales were $1,928.4 million, up 11.3% (5% organic), orders were $2,217.6 million, up 23.3% (22% organic), and the March-end backlog was $3,870.7 million; EIG had sales of $1,264.5 million and segment operating income of $373.9 million, while EMG had sales of $663.9 million and segment operating income of $170.8 million[7]. EIG organic sales grew only 2% in the first quarter, against 11% organic growth at EMG[8]. Second-quarter GAAP operating income was $528.2 million for a 25.8% margin, including $16.2 million of acquisition integration costs that cut the margin by 80 basis points; cost of sales was 64.0% of sales and net income was $406.9 million[3]. On the company's adjusted basis, second-quarter operating income was $544.4 million with a 26.6% margin, up 60 basis points, quarterly operating cash flow rose 35% to $483.7 million, and free cash flow equaled 111% of net income[4].

The balance sheet was still conservative before Indicor closed, but the financing was already in place. First-half operating cash flow was $935.2 million and free cash flow was $877.7 million, against $724.3 million a year earlier; on June 30 cash was $495.4 million, total debt, net was $2,036.2 million and the debt-to-capital ratio was 15.3%; the company raised its revolving credit commitments from $2.3 billion to $3.5 billion and extended them to 2031, with up to $1.0 billion available for the Indicor consideration, and signed a term loan of up to $4.0 billion in three tranches of $1.625 billion, $1.625 billion and $750 million, all at floating SOFR-based rates[3]. Full-year guidance has been raised twice: in April adjusted EPS guidance moved from $7.87 to $8.07 up to $7.94 to $8.14[12], and in August it rose again to $8.20 to $8.30[4]; management also guided full-year sales up about 10% with mid-to-high single-digit organic growth, capital expenditures of about $160 million, depreciation and amortization of about $430 million (including about $210 million of acquisition-related amortization), and free cash flow equal to 110% to 115% of net income[11].

Operating Model

Revenue follows a rhythm in which orders come first and shipments follow. Consolidated revenue is the sum of EIG and EMG sales, and each segment's sales can be broken into the prior-year base multiplied by organic growth, acquisition contribution and currency; the organic part depends on customers' capital projects and OEM production schedules, with orders entering backlog before converting to revenue as they ship. In the second quarter, process businesses grew in the high teens, led by semiconductor and energy, aerospace and defense grew mid-teens organically, power grew mid-single digits organically and automation and engineering grew mid-teens organically; the U.S. and Asia grew low double digits, Europe grew mid-single digits, and price increases more than offset inflation and tariffs[11]. The book-to-bill ratio shows how far orders run ahead of revenue: it was about 1.15 in the first quarter[7] and about 1.12 in the second[3], while Indicor, with about $1.1 billion of annual sales, counts as acquisition contribution from August 26[1].

Operating profit is set by three forces: volume leverage, productivity and acquisition dilution. Management cites incremental margins of about 40% in both segments and has raised its annual productivity target to $160 million[11]; working in the other direction are newly acquired businesses, as EIG's second-quarter operating margin was 28.0%, down from 29.7% a year earlier, with integration costs taking off 110 basis points and the dilutive effect of acquisitions another 120 basis points[3]. Below operating income sits interest: interest expense was $81.3 million in 2025[9], and in the second quarter of 2026 GAAP interest expense was $30.1 million, of which $10.0 million was acquisition-related financing cost, leaving adjusted interest expense of $20.1 million; adjusted EPS adds back after-tax acquisition intangible amortization, financing fees and integration costs, which totaled $0.32 per share in the second quarter[4].

Cash flow usually exceeds net income, and after the closing it will turn toward debt repayment. Capital spending is light, with 2026 guidance of about $160 million, roughly 2% of 2025 sales, and acquisition amortization is a non-cash charge, so 2025 free cash flow of $1,671.6 million exceeded net income of $1,480.1 million[9]; full-year guidance calls for free cash flow of 110% to 115% of net income, and operating working capital fell 220 basis points to 16.4% of sales in the second quarter[11]. Cash has historically gone mainly to acquisitions, with $933.2 million spent in 2025[9] and $424.5 million in the first half of 2026[3]; the Indicor consideration is funded through the existing credit facility and new debt[1], so repaying the new borrowings will absorb a substantial part of free cash flow from here.

Industry and Competitive Position

AMETEK's competitive advantage comes from a spread of niche market positions and low customer concentration. The annual report says EIG holds strong positions in niche segments of the process, power and industrial, and aerospace markets, and EMG in niche segments of aerospace and defense, automation and medical, with no single customer above 5% of company sales[9]. Management estimates that AI and data centers, defense modernization, commercial aerospace and power infrastructure together account for roughly half of revenue, with direct data center exposure smaller but growing rapidly, and second-quarter price increases more than offset inflation and tariffs, which indicates the company still has pricing power in these niches[11].

The weakness of this structure is volatility from order timing and international exposure. The annual report's risk factors say quarterly sales and profits depend substantially on the volume and timing of orders received in the quarter, and that demand in some businesses depends on customers' capital budgets and government funding policies[9]; international sales were 48.2% of the total in 2025[9] and 47.1% in the second quarter of 2026[3], so currency and tariffs affect both costs and translated revenue. The available materials contain no peer financial data, so this article cannot quantify AMETEK's share or margin gap against its main competitors.

Core Debates

Will record orders turn into revenue: can EIG convert its order surge into organic sales growth in the third quarter?

This question decides whether the company's main growth engine restarts. EIG produced 64.7% of revenue in the second quarter[11], and in 2025 its operating income of $1,447.1 million was about 70% of the two segments' combined $2,026.0 million, even though EIG organic sales fell 1% that year[9]. Management raised its second-half organic growth outlook by 1.5 to 2 percentage points, which assumes backlog ships on schedule[11].

The evidence shows strong orders but still slow conversion. Organic orders rose 22% and 25% in the first two quarters, with book-to-bill ratios of about 1.15 and 1.12[7][3]; backlog stood at $4,110.2 million on June 30, up 14.8% from the end of 2025, and EIG organic sales grew 7% in the second quarter[3]. Management said EIG organic orders grew 20% in the second quarter, with process businesses strongest in semiconductor and energy, while also describing the order cadence as "lumpy"[11]. An alternative explanation is that some orders are long-lead large projects or were placed ahead of price changes, which would lift backlog while converting slowly into current-quarter revenue.

The financial transmission runs from customer capital spending all the way to EIG operating income. Semiconductor equipment makers, energy and grid customers and data center operators order against their capital plans, which first builds EIG organic orders (up 20% in the second quarter) and company backlog ($4,110.2 million), then ships on lead times into EIG organic sales (up 7% in the second quarter), and finally reaches EIG sales and operating income (GAAP $369.7 million in the second quarter)[3]. At the second quarter's $1,321.2 million of EIG sales, each percentage point of organic growth moves quarterly revenue by about $13 million[3].

What remains unresolved is whether this conversion stays visible once acquisition contributions shift. Three things matter in the third quarter: whether EIG organic sales growth is at least the second quarter's 7%; whether company organic orders are still growing and book-to-bill stays above 1.0; and whether September 30 backlog, excluding what Indicor brings in, is at least $4,110.2 million. If EIG organic growth falls below 7% while backlog keeps rising, the slow-conversion explanation gains weight; if organic orders turn negative, the first-half order peak was concentrated in a few projects.

Can EMG keep its margin gains: will Paragon-led volume leverage hold up against tougher second-half comparisons?

This question decides how much operating support lies behind the raised profit guidance. EMG's operating margin rose from 20.0% in 2024 to 23.3% in 2025[9] and to 26.2% in the second quarter of 2026[3], and management said most of the margin expansion came from EMG, especially the Paragon medical components business[11]. If the expansion reflects sustainable volume growth, the profit guidance has support; if it reflects concentrated deliveries, second-half margins will fall back.

The evidence supports volume leverage but leaves room for concentrated deliveries. Second-quarter EMG sales were $723.2 million, up 15% organically, and operating income rose 31.6% to $189.3 million[3]; organic orders grew 35%, and management said Paragon finished its integration early during a demand downturn, so volume from new product introductions lifted margins sharply, with incremental margins of about 40% across both segments[11]. On the other hand, management warned in the first quarter that "EMG has tough comps later in year" and said the medical end market grew low double digits in the first quarter with tougher comparisons later[8]. Subtracting the first two quarters of 2025 from the annual report's full-year figures puts EMG's second-half 2025 operating margin at about 24.0%[9][7][3].

The financial transmission runs from OEM design wins to consolidated operating income. New device introductions at medical OEMs, semiconductor and automation equipment orders, and defense and commercial aviation thermal-management and repair demand drive EMG organic volume (up 15% in the second quarter, with organic orders up 35%), which turns into fixed-cost absorption through incremental margins of about 40%[11], and finally into EMG operating income ($189.3 million in the second quarter) and consolidated operating income[3]. On second-quarter sales, each percentage point of EMG margin is worth about $7 million of quarterly operating income[3].

What remains unresolved is how much of the high margin will fade as comparisons stiffen and acquisitions dilute. Three things matter in the third quarter: whether EMG's operating margin is at least 25% and above the second-half 2025 level of about 24.0%; whether EMG organic sales growth stays above 5%; and whether EMG organic orders are still growing at double digits, with medical and defense still the main sources. If the margin returns to around 24% while organic sales slow, the second quarter included concentrated deliveries such as medical customer restocking or a few large orders; the parts of First Aviation and Indicor that join EMG may also pull down the reported margin.

Is the $5 billion Indicor deal paying its way: how will its revenue, interest and integration costs show up in the third quarter?

This deal decides revenue growth, interest expense and GAAP profit for the second half of 2026 and for 2027. Indicor has about $1.1 billion of annual sales and profitability consistent with AMETEK, and the roughly $5.0 billion all-cash price is funded with credit facility borrowings and new debt[1]; against 2025 sales of $7,401.1 million, it adds about 15% to the existing revenue base[9]. The third quarter is the first report after closing and the first time the company may fold Indicor into its guidance.

The evidence so far gives only the outline of the deal, and post-closing costs have not been disclosed. The August 26 closing announcement said Indicor should add about $350 million to 2026 sales and be modestly accretive to 2026 adjusted EPS[5]; in June the company signed a term loan of up to $4.0 billion and expanded its revolver to $3.5 billion, and total debt, net was $2,036.2 million at the end of June[3]. The August 4 third-quarter guidance (sales up high single digits, adjusted EPS of $2.08 to $2.10) was issued before closing[4], and management said it was increasingly confident in 10% to 12% cost synergies[11]. An alternative view is that four integrations, FARO, LKC, First Aviation and Indicor, are running at once, so integration costs, acquisition amortization and interest will widen the gap between GAAP and adjusted profit, while the adjusted figures hide those costs.

The financial transmission runs from new debt to both measures of EPS. A $4.0 billion term loan plus up to $1.0 billion of revolver borrowing would take total debt from $2,036.2 million at the end of June to roughly the $7 billion range, with floating-rate interest rising accordingly[3]; at the same time Indicor's sales and profit enter EIG and EMG as acquisition contribution, bringing integration costs and acquisition amortization with them[1], and all of this flows through to GAAP and adjusted EPS and free cash flow. The second-quarter baselines are adjusted EPS of $2.09 and adjusted interest expense of $20.1 million (GAAP $30.1 million, including $10.0 million of acquisition financing cost)[4], plus a 5-percentage-point acquisition contribution to sales growth[3].

What remains unresolved is whether Indicor's revenue covers the new interest and integration costs. Three things matter in the third quarter: whether adjusted EPS lands at or above the $2.08 to $2.10 range and whether full-year guidance of $8.20 to $8.30 is maintained or raised; whether the company breaks out Indicor's sales contribution and reaffirms about $350 million for the year; and adjusted interest expense, September-end total debt and the gap between GAAP and adjusted EPS. If adjusted EPS falls below the bottom of guidance with interest and integration costs above plan, or if the overlapping integrations make segment performance hard to read, the deal is costing more than the current understanding assumes.

Risks and Falsifiers

Tariffs and currency act on both costs and translated revenue. International sales were $3,570.5 million, or 48.2% of the total, in 2025[9]; in the second quarter currency cut 3 percentage points from order growth and cost of sales was 64.0% of sales[3], while price increases more than offset inflation and tariffs[11]. If management again says in the third quarter that pricing covers inflation and tariffs, and cost of sales excluding Indicor integration costs is no higher than 64.0%, this risk has not materialized.

Slow order conversion would let backlog grow without lifting current-quarter revenue. Large orders such as data center grid simulation and semiconductor platforms[11] may ship over several quarters, and at second-quarter EIG sales of $1,321.2 million each lost percentage point of organic growth costs about $13 million of quarterly revenue and weighs on full-year organic guidance[3]. If third-quarter EIG organic sales grow at least 7% with book-to-bill above 1.0, this risk is falsified.

A fading order peak would weaken revenue support for 2027. Management describes the order cadence as uneven[11], and if the first half's 22% to 25% organic order growth came from a few large orders, third-quarter organic orders could decline year over year; the June-end backlog of $4,110.2 million equals roughly half a year of revenue[3]. If third-quarter organic orders grow more than 10%, this risk is falsified.

Inventory corrections at medical and automation customers would hit EMG profit directly. Paragon and other medical components and automation businesses depend on OEM production schedules, and with second-quarter EMG operating income of $189.3 million each percentage point of margin is worth about $7 million of quarterly operating income[3]. If third-quarter EMG organic sales grow more than 5% with a margin of at least 25%, this risk is falsified.

Financing costs rise with floating-rate borrowing. The Indicor price is funded almost entirely with debt, both the term loan and the revolver float with SOFR, and new borrowing could reach about $5 billion[3]; second-quarter adjusted interest expense of $20.1 million is the pre-closing base[4]. If the company discloses post-closing interest expense and maintains full-year adjusted EPS guidance, this risk has not materialized.

Integration load would widen the gap between GAAP and adjusted profit. Second-quarter integration costs for FARO, LKC and First Aviation were $16.2 million[3], adjusted EPS added back $0.32[4], and 2026 acquisition amortization is about $210 million[11], while Indicor's integration has only just begun. If the third-quarter gap between GAAP and adjusted EPS is not materially wider than $0.32 and the company reaffirms its synergy target, this risk is falsified.

What to Watch Next

• Order conversion: EIG organic sales growth against the second quarter's 7%; at least 7% supports conversion, while a lower rate with rising backlog points to slow conversion.
• Order momentum: organic orders against the second quarter's 25% and book-to-bill against about 1.12; organic orders up more than 10% with a ratio above 1.0 support demand, while a decline points to concentration in a few projects.
• Backlog: September 30 backlog excluding Indicor against $4,110.2 million on June 30; holding at or above that level supports continued demand.
• EMG margin: the third-quarter operating margin against 26.2% in the second quarter and about 24.0% in the second half of 2025; at least 25% supports volume leverage, while a return to about 24% points to concentrated deliveries.
• EMG volume: organic sales against 15% and organic orders against 35% in the second quarter; organic sales above 5% and double-digit order growth, led by medical and defense, support durability.
• Indicor and EPS: adjusted EPS against $2.09 in the second quarter and guidance of $2.08 to $2.10 for the quarter and $8.20 to $8.30 for the year; a result below $2.08 points to heavier interest and integration costs.
• Indicor disclosure: the stand-alone sales contribution against about $350 million for 2026, adjusted interest expense against $20.1 million, and September-end debt against $2,036.2 million at June 30; reaffirming about $350 million and holding guidance supports the deal logic.
• GAAP versus adjusted EPS: the third-quarter gap against $0.32 in the second quarter; a materially wider gap means the costs hidden by the adjusted figures are growing.

Conclusion

AMETEK's growth is driven by three things: orders created by customer capital spending, the speed at which those orders ship, and the revenue and costs that acquisitions bring. In the second quarter of 2026 the company set records with sales of $2,044.4 million, orders of $2,284.0 million and backlog of $4,110.2 million[3], posted adjusted EPS of $2.09 and raised full-year guidance to $8.20 to $8.30[4]; yet EIG organic sales grew only 7%, EMG's margin has already reached 26.2%, and the $5 billion Indicor deal moves the company from low leverage to debt-funded expansion[3][5]. The central open relationship is whether organic growth from order conversion and EMG's volume leverage can offset the interest, amortization and integration costs that Indicor brings.

The outside commentary published after the deal places the risk on acquisition costs rather than on demand. Panabee, in an August 4 article, argued that integrating Indicor alongside FARO, LKC and First Aviation creates operational strain, that the concentration of integration activity may obscure true segment performance, and that sustaining margins depends on how fast the new businesses deliver synergies[13]. Maham Fatima of Insider Monkey argued on September 19 that the gap between GAAP and adjusted earnings is widening, that adjusted figures smooth over the ongoing costs of acquisitions, and that the second half of 2026 will show whether the deal was well timed or simply well funded[14]. Both views map onto the Indicor debate, but Panabee focuses on operating execution and segment margins, which also bears on whether EMG can keep its margin gains, while Fatima focuses on costs smoothed over by the accounting presentation; neither piece addresses whether orders will turn into revenue, so that debate can for now be judged only from the company's own disclosures.

If the third quarter brings EIG organic sales growth of at least 7%, book-to-bill above 1.0, an EMG margin of at least 25%, and adjusted EPS at or above $2.08 to $2.10 with a GAAP-to-adjusted gap not materially wider than $0.32, the current understanding of durable demand and manageable acquisition costs would be strengthened. Conversely, if organic orders turn negative, EIG organic sales slow while backlog keeps piling up, the EMG margin returns to about 24%, or interest and integration costs push adjusted EPS below the bottom of guidance, that understanding would be materially weakened.

Sources

[1] AME Indicor agreement 8-K filed 2026-05-06 · 2026-05-06 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001037868&type=8-K

[2] AME earnings calendar updated 2026-10-29 · 2026-10-29 · Drillr earnings calendar · https://gateway.drillr.ai/mcp/private

[3] AME Q2 2026 10-Q filed 2026-08-04 · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/0001037868/000103786826000175/ame-20260630.htm

[4] AME Q2 2026 8-K filed 2026-08-04 · 2026-08-04 · 8-K · https://www.prnewswire.com/news-releases/ametek-announces-record-second-quarter-2026-results-and-raises-full-year-guidance-302841627.html

[5] AME Indicor closing 8-K filed 2026-08-26 · 2026-08-26 · 8-K · https://www.prnewswire.com/news-releases/ametek-completes-acquisition-of-indicor-instrumentation-302860916.html

[6] Drillr analyst estimates AME Q3 2026 retrieved 2026-10-29 · 2026-10-29 · Drillr analyst estimates · https://gateway.drillr.ai/mcp/private

[7] AME Q1 2026 10-Q filed 2026-04-30 · 2026-04-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/1037868/000103786826000144/

[8] AME Q1 2026 earnings call 2026-04-30 · 2026-04-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[9] AME FY2025 10-K filed 2026-02-17 · 2026-02-17 · 10-K · https://www.sec.gov/Archives/edgar/data/1037868/000103786826000016/

[10] AME First Aviation closing 8-K filed 2026-05-26 · 2026-05-26 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001037868&type=8-K

[11] AME Q2 2026 earnings call 2026-08-04 · 2026-08-04 · earnings-call · https://gateway.drillr.ai/mcp/private

[12] AME Q1 2026 8-K filed 2026-04-30 · 2026-04-30 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001037868&type=8-K

[13] Panabee view on AMETEK Q2 2026 2026-08-04 · 2026-08-04 · Panabee · https://www.panabee.com/news/ametek-earnings-q2-2026-report

[14] Insider Monkey view on AMETEK Indicor deal 2026-09-19 · 2026-09-19 · Insider Monkey · https://www.insidermonkey.com/news/ameteks-ame-5b-deal-bets-big-on-a-hot-streak-1840132/